Enalapril significantly reduced the incidence of diabetes compared to placebo in patients with left ventricular dysfunction (5.9% vs 22.4%; HR 0.22; 95% CI 0.10-0.46; P<0.0001).
Cohort (n=291)
Blinded reviewers
No
Does enalapril reduce the incidence of diabetes in non-diabetic patients with left ventricular dysfunction?
Enalapril significantly reduces the incidence of new-onset diabetes in patients with left ventricular dysfunction, particularly those with impaired fasting glucose at baseline.
Effect estimate: HR 0.22 (95% CI 0.10-0.46)
Absolute Event Rate: 5.9% vs 22.4%
p-value: p=<0.0001
BACKGROUND: Diabetes mellitus is a predictor of morbidity and mortality in patients with heart failure. The effect of angiotensin-converting enzyme (ACE) inhibitors on the prevention of diabetes in patients with left ventricular dysfunction is unknown. The aim of this retrospective study was to assess the effect of the ACE inhibitor enalapril on the incidence of diabetes in the group of patients from the Montreal Heart Institute enrolled in the Studies of Left Ventricular Dysfunction (SOLVD). METHODS AND RESULTS: Clinical charts were evaluated for fasting plasma glucose (FPG) levels by blinded reviewers. A diagnosis of diabetes was made when a FPG > or =126 mg/dL (7 mmol/L) was found at 2 visits (follow-up, 2.9+/-1.0 years). Of the 391 patients enrolled at the Montreal Heart Institute, 291 were not diabetic (FPG <126 mg/dL without a history of diabetes), 153 of these were on enalapril and 138 were on placebo. Baseline characteristics were similar in the 2 groups. Forty patients developed diabetes during follow-up, 9 (5.9%) in the enalapril group and 31 (22.4%) in the placebo group (P<0.0001). By multivariate analysis, enalapril remained the most powerful predictor for risk reduction of developing diabetes (hazard ratio, 0.22; 95% confidence intervals, 0.10 to 0.46; P<0.0001). The effect of enalapril was striking in the subgroup of patients with impaired FPG (110 mg/dL 6.1 mmol/L < or =FPG <126 mg/dL) at baseline: 1 patient (3.3%) in the enalapril group versus 12 (48.0%) in the placebo group developed diabetes (P<0.0001). CONCLUSIONS: Enalapril significantly reduces the incidence of diabetes in patients with left ventricular dysfunction, especially those with impaired FPG.
Vermès et al. (Mon,) conducted a cohort in Chronic Heart Failure with left ventricular dysfunction (n=291). Enalapril vs. Placebo was evaluated on Incidence of diabetes (fasting plasma glucose >=126 mg/dL at 2 visits) (HR 0.22, 95% CI 0.10-0.46, p=<0.0001). Enalapril significantly reduced the incidence of diabetes compared to placebo in patients with left ventricular dysfunction (5.9% vs 22.4%; HR 0.22; 95% CI 0.10-0.46; P<0.0001).